Dr Yap on the Investigation of Saruparib in Solid Tumors
Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for investigating saruparib in advanced solid tumors, such as prostate cancer with genetic mutations.
Source: onclive.com
Phasei Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Phasei Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Phasei Program Today - Breaking & Trending Today
First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors
Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.
Source: onclive.com
Dr Richardson on the Safety of Upifitamab Rilsodotin in Platinum-Resistant Ovarian Cancer
Debra L. Richardson, MD, FACS, FACOG, discusses the safety profile of upifitamab rilsodotin in the phase 1/2 UPLIFT trial of patients with ovarian cancer.
Source: onclive.com
Dr Richardson on the UPLIFT Trial of Upifitamab Rilsodotin in Ovarian Cancer
Debra L. Richardson, MD, FACS, FACOG, discusses outcomes seen with upifitamab rilsodotin in the phase 1/2 UPLIFT trial for patients with ovarian cancer.
Source: onclive.com
Journey Ends for Upifitamab Rilsodotin in NaPi2b+ Platinum-Resistant Ovarian Cancer
Debra L. Richardson, MD, FACS, FACOG, expands on results with upifitamab rilsodotin in platinum-resistant high-grade serous ovarian cancer.
Source: onclive.com